A Phase 2 interventional study of SP-102 in Lumbosacral Radicular Pain, sponsored by Semnur Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-01-13.
Sponsored by Semnur Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Sciatica with a site in United States — 7 open to participants now, 7 under way, none of them phase 3. Sciatica · United States.
Among the 42 studies in Sciatica with a site in United States, this one is the 35th largest by enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2018, is one of 11 in phase 2, and was the 29th registered.
149 studies on the registry are indexed under Sciatica; 31 are open to participants now.
Browse Sciatica studies →7 of the 42 studies in Sciatica with a site in United States are open now. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
Northwestern University · Sites in United States, Thailand, Ukraine
Consano Bio · Sites in United States, Australia
Ages 18–70
National University of Natural Medicine · Sites in United States
Ages 18–75
University of California, San Diego · Sites in United States
Ages 21–65 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Sciatica studies recruiting now, 5 (28%) set no upper age limit and 12 (67%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 15 · Phase 3 6 · Phase 4 1
First in 1999; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 68 across 122 interventional studies indexed under Sciatica.
Median enrollment 78 across the 38 interventional studies, 38 across the 4 observational. Of the 31 that completed or were terminated, 11 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 42 have an industry lead sponsor. The 10 most frequent:
Semnur Pharmaceuticals, Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Semnur Pharmaceuticals, Inc. has 2 studies filed under Sciatica — fewer than ten, so there is no comparison to draw.
5 of the studies in Sciatica with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07125027National University of Natural MedicineA Multicomponent Intervention for Patients With Lumbosacral Radiculopathy: Move-MORE | 2026-11 |
| NCT07397117University of California, San FranciscoComparing Ultrasound-Guided Transgluteal Nerve Block to Standard Care | 2026-12-31 |
| NCT04982965University of California, San DiegoBrain Mechanisms Supporting Cannabis-induced Pain Relief | 2027-01-15 |
| NCT07494136University of MiamiDose Dependent Steroid Injections | 2027-05 |
| NCT07264270Consano BioStudy to Evaluate Safety of C-1101 Versus Sterile Saline in Adults With Chronic Painful Lumbosacral Radiculopathy | 2027-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 42 studies in Sciatica with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, single-arm, repeat dose study to characterize the pharmacodynamics and safety/tolerability of SP-102 administered by epidural injection.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SP-102
Drug: SP-102
Injection
Change in Plasma Cortisol Concentrations From Baseline
Dexamethasone-induced hypothalamic-pituitary-adrenal (HPA) suppression is evaluated by monitoring SP-102 induced changes in plasma cortisol levels from Baseline. The T1 (index) and T2 (repeat) injections of SP-102 are separated by 4-8 weeks
Time frame: 12 Weeks
Change in Blood Glucose Levels From Baseline
Dexamethasone-induced hypothalamic-pituitary-adrenal (HPA) suppression is evaluated by monitoring SP-102 induced changes in blood glucose levels from Baseline. The T1 (index) and T2 (repeat) injections of SP-102 are separated by 4-8 weeks
Time frame: 12 Weeks
Change in White Blood Cell (WBC) Levels From Baseline
Dexamethasone-induced hypothalamic-pituitary-adrenal (HPA) suppression is evaluated by monitoring SP-102 induced changes in WBC levels from Baseline. The T1 (index) and T2 (repeat) injections of SP-102 are separated by 4-8 weeks
Time frame: 12 Weeks
Change in Numeric Pain Rating Scale (NPRS) Scores for Leg Pain From Baseline
The NPRS is an 11-point scale (0- to 10-point scale where 0 is no pain and 10 is worst pain imaginable) that allows subjects to rate the severity of their pain intensity at various points in time (Turk et al., 2003). Subjects used the NPRS to record their current pain, average pain over 24 hours, and worst pain over 24 hours for both affected leg(s) and back pain. NPRS average leg pain scores over 24 hours are presented.
Time frame: 12 weeks
Change in Numeric Pain Rating Scale (NPRS) Scores for Back Pain From Baseline
The NPRS is an 11-point scale (0- to 10-point scale where 0 is no pain and 10 is worst pain imaginable) that allows subjects to rate the severity of their pain intensity at various points in time (Turk et al., 2003). Subjects used the NPRS to record their current pain, average pain over 24 hours, and worst pain over 24 hours for both affected leg(s) and back pain. NPRS average back pain scores over 24 hours are presented.
Time frame: 12 weeks
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Incidence of treatment-emergent AEs (TEAEs) related to study drug.
Time frame: 12 weeks
| Milestone | SP-102 |
|---|---|
| Started | 19 |
| Completed | 19 |
| Not completed | 0 |
Dexamethasone-induced hypothalamic-pituitary-adrenal (HPA) suppression is evaluated by monitoring SP-102 induced changes in plasma cortisol levels from Baseline. The T1 (index) and T2 (repeat) injections of SP-102 are separated by 4-8 weeks
| nmol/L | SP-102 |
|---|---|
| T1: Day 1 (predose) | 36.62 ± 31.81 |
| T1: Day 2 | 0.64 ± 0.27 |
| T1: Day 3 | 6.26 ± 9.00 |
| T1: Day 4 | 29.77 ± 2.60 |
| T1: Day 5 | 39.91 ± 40.53 |
| T1: Day 8 | 39.71 ± 28.97 |
| T1: Day 15 | 44.28 ± 33.55 |
| T1: Day 28 | 25.08 ± 21.34 |
| T2: Day 1 (predose) | 38.81 ± 41.10 |
| T2: Day 2 | 0.64 ± 0.23 |
| T2: Day 3 | 3.68 ± 3.85 |
| T2: Day 4 | 50.71 ± 56.21 |
| T2: Day 5 | 38.35 ± 35.00 |
| T2: Day 8 | 41.73 ± 38.95 |
| T2: Day 15 | 73.31 ± 97.64 |
| T2: Day 28 | 28.18 ± 20.34 |
Dexamethasone-induced hypothalamic-pituitary-adrenal (HPA) suppression is evaluated by monitoring SP-102 induced changes in blood glucose levels from Baseline. The T1 (index) and T2 (repeat) injections of SP-102 are separated by 4-8 weeks
| nmol/L | SP-102 |
|---|---|
| T1: Day 1 (predose) | 4.993 ± 0.5216 |
| T1: Day 2 | 6.155 ± 0.9009 |
| T1: Day 3 | 4.528 ± 0.4451 |
| T1: Day 4 | 4.676 ± 0.5509 |
| T1: Day 5 | 4.958 ± 0.4362 |
| T1: Day 8 | 5.059 ± 0.6597 |
| T1: Day 15 | 5.254 ± 0.8143 |
| T1: Day 28 | 4.963 ± 0.7116 |
| T2: Day 1 (predose) | 4.867 ± 0.5655 |
| T2: Day 2 | 5.865 ± 0.8673 |
| T2: Day 3 | 4.581 ± 0.4986 |
| T2: Day 4 | 4.850 ± 0.8078 |
| T2: Day 5 | 4.959 ± 0.5791 |
| T2: Day 8 | 4.821 ± 0.4463 |
| T2: Day 15 | 5.237 ± 0.8394 |
| T2: Day 28 | 4.945 ± 0.5959 |
Dexamethasone-induced hypothalamic-pituitary-adrenal (HPA) suppression is evaluated by monitoring SP-102 induced changes in WBC levels from Baseline. The T1 (index) and T2 (repeat) injections of SP-102 are separated by 4-8 weeks
| cell count × 10^9/L | SP-102 |
|---|---|
| T1: Day 1 (predose) | 6.65 ± 2.051 |
| T1: Day 2 | 13.43 ± 3.726 |
| T1: Day 3 | 9.33 ± 2.336 |
| T1: Day 4 | 7.38 ± 1.863 |
| T1: Day 5 | 6.81 ± 1.771 |
| T1: Day 8 | 6.91 ± 2.212 |
| T1: Day 15 | 7.26 ± 1.873 |
| T1: Day 28 | 6.15 ± 1.339 |
| T2: Day 1 (predose) | 6.77 ± 1.865 |
| T2: Day 2 | 13.43 ± 4.517 |
| T2: Day 3 | 9.21 ± 3.199 |
| T2: Day 4 | 7.88 ± 2.302 |
| T2: Day 5 | 7.28 ± 2.087 |
| T2: Day 8 | 7.31 ± 2.803 |
| T2: Day 15 | 8.05 ± 3.592 |
| T2: Day 28 | 6.07 ± 1.541 |
The NPRS is an 11-point scale (0- to 10-point scale where 0 is no pain and 10 is worst pain imaginable) that allows subjects to rate the severity of their pain intensity at various points in time (Turk et al., 2003). Subjects used the NPRS to record their current pain, average pain over 24 hours, and worst pain over 24 hours for both affected leg(s) and back pain. NPRS average leg pain scores over 24 hours are presented.
| score on a scale | SP-102 |
|---|---|
| T1: Baseline (pre-dose) | 5.4 ± 1.30 |
| T1: Day 1 | 5.3 ± 1.29 |
| T1: Day 2 | 3.2 ± 1.84 |
| T1: Day 3 | 2.2 ± 1.61 |
| T1: Day 4 | 2.5 ± 2.14 |
| T1: Day 5 | 2.3 ± 2.21 |
| T1: Day 8 | 2.5 ± 2.37 |
| T1: Day 15 | 3.2 ± 2.48 |
| T1: Day 28 | 3.4 ± 1.80 |
| T2: Baseline (pre-dose) | 5.4 ± 1.18 |
| T2: Day 1 | 5.2 ± 1.32 |
| T2: Day 2 | 3.5 ± 2.36 |
| T2: Day 3 | 1.9 ± 1.28 |
| T2: Day 4 | 2.1 ± 1.58 |
| T2: Day 5 | 1.9 ± 1.53 |
| T2: Day 8 | 2.2 ± 2.21 |
| T2: Day 15 | 2.4 ± 2.21 |
| T2: Day 28 | 2.9 ± 2.46 |
The NPRS is an 11-point scale (0- to 10-point scale where 0 is no pain and 10 is worst pain imaginable) that allows subjects to rate the severity of their pain intensity at various points in time (Turk et al., 2003). Subjects used the NPRS to record their current pain, average pain over 24 hours, and worst pain over 24 hours for both affected leg(s) and back pain. NPRS average back pain scores over 24 hours are presented.
| score on a scale | SP-102 |
|---|---|
| T1: Baseline (pre-dose) | 5.2 ± 1.46 |
| T1: Day 1 | 5.2 ± 1.50 |
| T1: Day 2 | 3.5 ± 2.14 |
| T1: Day 3 | 2.3 ± 1.45 |
| T1: Day 4 | 2.7 ± 2.11 |
| T1: Day 5 | 2.6 ± 2.39 |
| T1: Day 8 | 2.8 ± 2.48 |
| T1: Day 15 | 3.2 ± 2.46 |
| T1: Day 28 | 3.9 ± 1.90 |
| T2: Baseline (pre-dose) | 5.4 ± 1.35 |
| T2: Day 1 | 5.3 ± 1.35 |
| T2: Day 2 | 3.5 ± 2.33 |
| T2: Day 3 | 2.1 ± 1.55 |
| T2: Day 4 | 2.8 ± 1.81 |
| T2: Day 5 | 2.3 ± 1.35 |
| T2: Day 8 | 2.4 ± 2.03 |
| T2: Day 15 | 2.9 ± 1.96 |
| T2: Day 28 | 3.2 ± 2.27 |
Incidence of treatment-emergent AEs (TEAEs) related to study drug.
| events | SP-102 |
|---|---|
| Treatment 1 | 20 |
| Treatment 2 | 10 |
Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SP-102 | 0/19 (0%) | 0/19 (0%) | 13/19 (68.4%) |
| Event | SP-102 |
|---|---|
| HeadacheNervous system disorders | 7/19 |
| DyspepsiaGastrointestinal disorders | 2/19 |
| NasopharyngitisInfections and infestations | 2/19 |
| Tooth abscessInfections and infestations | 2/19 |
| Abdominal discomfortGastrointestinal disorders | 1/19 |
| Abdominal painGastrointestinal disorders | 1/19 |
| Abdominal pain upperGastrointestinal disorders | 1/19 |
| Food poisoningGastrointestinal disorders | 1/19 |
| Gastrooesophageal refluxdiseaseGastrointestinal disorders | 1/19 |
| PainGeneral disorders | 1/19 |
| Age, Continuous(years) | SP-102 |
|---|---|
| Mean | 54.8 ± 14.42 |
| Sex: Female, Male(Participants) | SP-102 |
|---|---|
| Female | 12 |
| Male | 7 |
| Ethnicity (NIH/OMB)(Participants) | SP-102 |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 16 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | SP-102 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 19 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Height(cm) | SP-102 |
|---|---|
| Mean | 166.51 ± 12.294 |
| Weight(kg) | SP-102 |
|---|---|
| Mean | 84.03 ± 16.412 |
| BMI(kg/m^2) | SP-102 |
|---|---|
| Mean | 30.51 ± 6.127 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2018 to primary completion in Mar 2019, 8 months.
Results were first posted in Jan 2022, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SP-102
Semnur Pharmaceuticals, Inc.